All In Biotech

Drug Trial Radar · NCT01020019

Combined Pharmacotherapy for Cannabis Dependency

A Randomized, Double-Blind, Placebo-Controlled Study of Lofexidine and Dronabinol for the Treatment of Marijuana Dependence

Last checked: Nov 20, 2026Latest source record: Apr 24, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

156

Actual

Start

Jan 2010

Primary completion

Sep 2014

Study completion Sep 2014

Sponsor

Lead sponsor
New York State Psychiatric InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Drug Abuse (NIDA)
First posted
Nov 25, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to see if Lofexidine in combination with Marinol is superior to placebo in achieving abstinence, reducing cannabis use and reducing withdrawal in cannabis-dependent patients seeking treatment for their marijuana use.

Conditions

  • Cannabis Dependence
  • Marijuana Dependence

Interventions

  • DronabinolDrug

    Dronabinol: 20 mg/TID

  • PlaceboDrug

    Placebo control

  • LofexidineDrug

    Lofex: .6 mg/ TID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 21 Days of Consecutive Abstinence as Measured by the Time-line Followback.Time frame: reported daily for 12 weeks/ or study participation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New York State Psychiatric Institute

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.